About Hummingbird Bioscience
Hummingbird Bioscience is a company based in Singapore (Singapore) founded in 2015 by Lan Zhang and Jerome Boyd-Kirkup. Hummingbird Bioscience has raised $150 million across 6 funding rounds from investors including SK, Frazier Healthcare Partners and Novo Holdings. Hummingbird Bioscience offers products and services including ADC Platform and Antibody Platform. Hummingbird Bioscience operates in a competitive market with competitors including ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
- Headquarter Singapore, Singapore
- Founders Lan Zhang, Jerome Boyd-Kirkup
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website hummingbirdbioscience.com
- Social LinkedIn X Facebook YouTube
- Total Equity Funding$150 M (USD)
in 6 rounds
- Latest Funding Round$125 M (USD), Series C
May 2021
- InvestorsSK
& 22 more
Products & Services of Hummingbird Bioscience
Hummingbird Bioscience offers a comprehensive portfolio of products and services, including ADC Platform and Antibody Platform.
Platform for developing antibody-drug conjugates targeting cancer.
Technology for engineering precision antibody therapeutics.
Apps and channels of Hummingbird Bioscience
its YouTube channel Hummingbird Bioscience has 27 subscribers and 9 videos.
Videos from Hummingbird Bioscience
The most watched videos on Hummingbird Bioscience's YouTube channel, Hummingbird Bioscience (27 subscribers). Click a video to play it here.
More on Hummingbird Bioscience.
Funding Insights of Hummingbird Bioscience
Hummingbird Bioscience has successfully raised a total of $150M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150.0M
- Total Rounds 6
- Last Round Series C — $125.0M
- Investors Count 23
All 6 funding rounds of Hummingbird Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $125.0M | Series C | – | Novo Holdings | |
| May 2020 | $6.0M | Series B | – | SK | |
| Dec 2019 | $19.0M | Series B | – | GNTech Venture Capital , Mirae Asset Venture | |
| Jul 2019 | – | Series A | – | Heritas Capital Management | |
| Feb 2019 | $13.1M | Grant | – | – | |
| May 2017 | – | Series A | – | Decheng Capital | – |
23 investors in total: 23 institutional.
Investors in Hummingbird Bioscience
Hummingbird Bioscience has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include SK, Frazier Healthcare Partners and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Investments in healthcare startups are managed by Octagon Capital Advisors. | – | octagoninvestments.com | New York, United States | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | – | edbi.com | Singapore, Singapore | |
Venture capital is invested in innovative drug development companies. | – | pureosbio.com | Pfäffikon, Switzerland | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Droia Ventures is focused on investing in drug development companies. | – | droiaventures.com | Luxembourg, Luxembourg | |
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China | |
Long-term investments in healthcare companies are managed by Altium Capital. | 2017 | altiumcap.com | New York, United States | |
Private equity and venture capital investment firm | – | heritascapital.com | Singapore, Singapore |
Investor details for Hummingbird Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hummingbird Bioscience
2 people are tracked at Hummingbird Bioscience (2 in leadership).
| Name | Role | Group |
|---|---|---|
Lan Zhang | Co-Founder | Leadership |
Jerome Boyd-Kirkup | Co-Founder & CSO | Leadership |
Complete people profiles for Hummingbird Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hummingbird Bioscience
3 dated milestones of Hummingbird Bioscience across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Hummingbird Bioscience is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $125.0M.
Competitors of Hummingbird Bioscience
Hummingbird Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alxoncology.com | 2015 | Burlingame, United States | $123.0M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493.0M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.2M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| alector.com | 2013 | San Francisco, United States | $214.8M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.1M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. |
Detailed competitors of Hummingbird Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hummingbird Bioscience
The website of Hummingbird Bioscience (hummingbirdbioscience.com) receives about 5K visits a month and ranks #1,579,101 among all websites worldwide, #2,112 in Biotechnology and Pharmaceuticals.
- Monthly visits5K
▼ 55.9% vs previous month
- Unique visitors5K
per month
- Global rank#1,579,101
among all websites
- Category rank#2,112
Health · Biotechnology and Pharmaceuticals
- Bounce rate23%
- Pages per visit3.4
- Average visit2 min 52 sec
- DevicesDesktop 12% · Mobile 88%
Websites whose visitors overlap most with Hummingbird Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| senseibio.com | 100% | 4.5K | #4,696,262 | View details | |
| kinetabio.com | 27% | – | – | View details |
Latest news on Hummingbird Bioscience
Complete news archive for Hummingbird Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Hummingbird Bioscience
10 companies that operate in the same segment as Hummingbird Bioscience (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 | |
Immunotherapeutics for cancer treatment are developed to target solid tumors. | 2017 | San Diego, California, United States | USD 181 M | USD 10 M | 81 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Hummingbird Bioscience
Hummingbird Bioscience was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Hummingbird Bioscience is headquartered in Singapore, Singapore.
Hummingbird Bioscience is a funded company, having raised a total of $150M across 6 funding rounds to date.
The company was founded in 2015 in Singapore and operates in the biotechnology sector. Antibodies for cancer therapy are developed through systems immunology and computational structural biology. Platform technology is utilized for the design of therapeutic antibodies. The pipeline includes HMBD-001, a monoclonal antibody, and HMBD-002, an anti-VISTA monoclonal antibody targeted at cancer treatment.
Hummingbird Bioscience's top competitors include Alector, Lyell Immunopharma and Alpine Immune Sciences.
Hummingbird Bioscience offers ADC Platform and Antibody Platform.
Hummingbird Bioscience has 23 investors. Key investors include SK, Frazier Healthcare Partners, Novo Holdings, Octagon Capital Advisors, and EDBI.